Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1Bronchiolitis Obliterans Syndrome 1

Interventions

fludarabine 2Sirolimus 2Mycophenolic Acid 2Filgrastim 2Cyclophosphamide 2posaconazole 1pegfilgrastim 1obinutuzumab 1montelukast 1ibrutinib 1Whole-Body Irradiation 1Voriconazole 1Tomography, X-Ray Computed 1Respiratory Function Tests 1Prednisone 1Mesna 1Interleukin-15 1Erythropoietin 1Electrocardiography 1Busulfan 1Budesonide 1Blood Transfusion 1Beclomethasone 1B3(Fv)-PE38KDEL recombinant immunotoxin 1Azithromycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Bronchiolitis Obliterans Syndrome × Beclomethasone × Clear all
NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 15 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡